A physiologically‐based pharmacokinetic precision dosing approach to manage dasatinib drug–drug interactions.

Autor: Kovar, Christina^1,2 (AUTHOR), Loer, Helena Leonie Hanae¹ (AUTHOR), Rüdesheim, Simeon^1,2 (AUTHOR), Fuhr, Laura Maria¹ (AUTHOR), Marok, Fatima Zahra¹ (AUTHOR), Selzer, Dominik¹ (AUTHOR), Schwab, Matthias^2,3,4 (AUTHOR), Lehr, Thorsten¹ (AUTHOR) thorsten.lehr@mx.uni‐saarland.de

Publikováno v: CPT: Pharmacometrics & Systems Pharmacology. Jul2024, Vol. 13 Issue 7, p1144-1159. 16p.

Dasatinib induces endothelial dysfunction leading to impaired recovery from ischaemia.

Autor: Gover-Proaktor A; Felsenstein Medical Research Center, Rabin Medical Center, Petah Tikva, Israel., Leshem-Lev D; Felsenstein Medical Research Center, Rabin Medical Center, Petah Tikva, Israel., Winograd-Katz S; Department of Immunology and Regenerative Biology, The Weizmann Institute of Science, Rehovot, Israel., Partouche S; Felsenstein Medical Research Center, Rabin Medical Center, Petah Tikva, Israel., Samara A; Felsenstein Medical Research Center, Rabin Medical Center, Petah Tikva, Israel., Shapira S; Felsenstein Medical Research Center, Rabin Medical Center, Petah Tikva, Israel., Nardi-Agmon I; Department of Cardiology, Rabin Medical Center, Petah Tikva, Israel., Harari E; Cardiology Division, Assuta Ashdod University Hospital, Ben-Gurion University of the Negev, Ashdod, Israel., Younis A; Felsenstein Medical Research Center, Rabin Medical Center, Petah Tikva, Israel., Najjar A; Department of Pathology, Rabin Medical Center, Petah Tikva, Israel., Kornowski R; Department of Cardiology, Rabin Medical Center, Petah Tikva, Israel.; The Faculty of Medicine and Health Sciences, Tel Aviv University, Tel Aviv, Israel., Geiger B; Department of Immunology and Regenerative Biology, The Weizmann Institute of Science, Rehovot, Israel., Raanani P; The Faculty of Medicine and Health Sciences, Tel Aviv University, Tel Aviv, Israel.; Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel., Leader A; Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel.; Memorial Sloan Kettering Cancer Center, New York, New York, USA., Granot G; Felsenstein Medical Research Center, Rabin Medical Center, Petah Tikva, Israel.; The Faculty of Medicine and Health Sciences, Tel Aviv University, Tel Aviv, Israel.

Publikováno v: British journal of haematology [Br J Haematol] 2024 Sep; Vol. 205 (3), pp. 1011-1016. Date of Electronic Publication: 2024 Jun 15.

Despite warnings, co‐medication with proton pump inhibitors and dasatinib is common in chronic myeloid leukemia, but XS004, a novel oral dasatinib formulation, provides reduced pH‐dependence, minimizing undesirable drug–drug interactions

Autor: Larfors, Gunnar¹ (AUTHOR) gunnar.larfors@medsci.uu.se, Andersson, Per² (AUTHOR), Jesson, Gérald² (AUTHOR), Liljebris, Charlotta² (AUTHOR), Brisander, Magnus² (AUTHOR), Lennernäs, Hans³ (AUTHOR), Stenke, Leif⁴ (AUTHOR)

Publikováno v: European Journal of Haematology. Oct2023, Vol. 111 Issue 4, p644-654. 11p.

Proven Cytomegalovirus Colitis Associated with Dasatinib Administration in Two Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Recipients.

Autor: Jeong Min Kim¹, Hyun Mi Kang^1,2, In Hyuk Yoo¹ yoohymn@naver.com, Dong-Gun Lee^2,3, Nack-Gyun Chung^1,4, Bin Cho^1,4

Publikováno v: Pediatric Gastroenterology, Hepatology & Nutrition. Jul2023, Vol. 26 Issue 4, p224-229. 6p.

Manifesting the Dasatinib-gallic acid co-amorphous system to augment anticancer potential: Physicochemical characterization, in silico molecular simulation, ex vivo permeability, and in vitro efficacy.

Autor: Kanp T; Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, Telangana 500037, India., Dhuri A; Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, Telangana 500037, India., Aalhate M; Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, Telangana 500037, India., Mahajan S; Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, Telangana 500037, India., Munagalasetty S; Department of Pharmacoinformatic, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, Telangana 500037, India., Kumar Sah S; Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Kolkata, West Bengal 700054, India., Kaity S; Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Kolkata, West Bengal 700054, India., Sharma B; Materials Research Centre, Malaviya National Institute of Technology (MNIT), Jaipur, Rajasthan, India., Bhandari V; Department of Pharmacoinformatic, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, Telangana 500037, India., Kumar Singh P; Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, Telangana 500037, India. Electronic address: pankajksingh3@gmail.com.

Publikováno v: International journal of pharmaceutics [Int J Pharm] 2024 Nov 15; Vol. 665, pp. 124672. Date of Electronic Publication: 2024 Sep 07.